Radiopharm Theranostics Files 6-K for February 2025
Ticker: RDPTF · Form: 6-K · Filed: Feb 10, 2025 · CIK: 1949257
| Field | Detail |
|---|---|
| Company | Radiopharm Theranostics Ltd (RDPTF) |
| Form Type | 6-K |
| Filed Date | Feb 10, 2025 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: reporting, foreign-private-issuer
TL;DR
Radiopharm Theranostics filed its monthly 6-K, confirming its status as a foreign private issuer reporting under Form 20-F.
AI Summary
Radiopharm Theranostics Limited filed a Form 6-K on February 10, 2025, reporting for the month of February 2025. The company is a foreign private issuer and will file annual reports under Form 20-F. Its principal executive office is located at Level 3, 62 Lygon Street, Carlton South, Victoria, 3053, Australia.
Why It Matters
This filing indicates ongoing reporting compliance for Radiopharm Theranostics as a foreign private issuer, which is standard for companies listed on US exchanges but based internationally.
Risk Assessment
Risk Level: low — This is a routine reporting form for a foreign private issuer and does not contain new material financial or operational information.
Key Players & Entities
- Radiopharm Theranostics Limited (company) — Registrant
- 001-41621 (company) — Commission File Number
- Level 3, 62 Lygon Street, Carlton South, Victoria, 3053, Australia (company) — Principal executive office address
- February 2025 (date) — Reporting period
- Form 20-F (company) — Annual report form
FAQ
What is the purpose of a Form 6-K filing?
A Form 6-K is a report of foreign private issuers required to be filed with the SEC pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934, typically to provide information that the company makes or is required to make public in its home country.
Which annual report form does Radiopharm Theranostics file?
Radiopharm Theranostics files its annual reports under cover of Form 20-F.
What is the principal executive office address of Radiopharm Theranostics?
The principal executive office is located at Level 3, 62 Lygon Street, Carlton South, Victoria, 3053, Australia.
What is the Commission File Number for Radiopharm Theranostics?
The Commission File Number for Radiopharm Theranostics is 001-41621.
For which month is this Form 6-K reporting?
This Form 6-K is reporting for the month of February 2025.
Filing Stats: 322 words · 1 min read · ~1 pages · Grade level 19.2 · Accepted 2025-02-10 08:00:13
Filing Documents
- ea0230478-6k_radiopharm.htm (6-K) — 19KB
- ea023047801ex99-1_radiopharm.htm (EX-99.1) — 16KB
- ex99-1_001.jpg (GRAPHIC) — 4KB
- 0001213900-25-011504.txt ( ) — 42KB
From the Filing
OF FOREIGN PRIVATE ISSUER UNITED SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of February 2025 Commission File Number: 001-41621 RADIOPHARM THERANOSTICS LIMITED (Name of Registrant) Level 3, 62 Lygon Street, Carlton South, Victoria, 3053, Australia (Address of principal executive office) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F Form 40-F Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934. Yes No If “Yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82- RADIOPHARM THERANOSTICS LIMITED EXPLANATORY NOTE Radiopharm Theranostics Limited (the “Company”) published one announcement (the “Public Notice”) to the Australian Securities Exchange on February 10, 2025 titled: - “Clinical trial data shows RAD 101 detects Brain Metastases” A copy of the Public Notice is attached as an exhibit to this report on Form 6-K. This report on Form 6-K (including the exhibit hereto) shall not be deemed to be “filed” for purposes of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) and shall not be incorporated by reference into any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing. 1 EXHIBITS Exhibit Number Description 99.1 Clinical trial data shows RAD 101 detects Brain Metastases 2 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. RADIOPHARM THERANOSTICS LIMITED Date: February 10, 2025 By: /s/ Phillip Hains Phillip Hains Company Secretary 3